“
TL;DR
This narrative review summarizes how organ-on-chip technology, which uses microfluidic devices with living human cells to mimic organ functions, can address limitations of traditional animal models in drug development.
Frontiers in Pharmacology · 5 authors, 2 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This narrative review summarizes how organ-on-chip technology, which uses microfluidic devices with living human cells to mimic organ functions, can address limitations of traditional animal models in drug development.
This narrative review describes organ-on-chip (OOC) platforms as advanced in vitro models that use microfluidic channels with living human cells to mimic organ physiology and disease. It argues OOC technology can overcome challenges of human relevance and reproducibility faced by animal and 2D in vitro models, potentially accelerating drug discovery. Limitations include the need for new platform materials (e.g., to reduce PDMS absorption) and standardized models for complex diseases. The authors suggest future directions such as real-time monitoring and integration of omics data.